Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the drug baricitinib for treating Juvenile Idiopathic Arthritis JIA in children and adolescents aged 1 to less than 18 years. This Phase 3 study focuses on participants who have already taken part in previous baricitinib studies for JIA to understand long-term effects. Participants receive baricitinib orally as the study treatment. This is a single-group study, meaning all participants will take baricitinib without comparison to a placebo or other drugs. The study follows participants for up to 264 weeks about 5 years to monitor treatment effects and safety over a long period. During the study, researchers will track serious adverse events, any permanent stops of baricitinib, and various measures of disease activity, pain, and skin condition related to JIA. These include assessments like the Pediatric American College of Rheumatology response index and Juvenile Arthritis Disease Activity Score. Participants will be monitored regularly throughout the study to evaluate health and immune responses while taking the study drug.
Actively Recruiting
Researchers are conducting a prospective, multicenter observational study to identify clinical and molecular biomarkers linked to treatment response, disease recurrence, progression, and survival in adults with colorectal cancer. The study aims to improve understanding of tumor biology and clinical outcomes by collecting detailed clinical data and biological samples from patients undergoing surgical resection for colorectal cancer. About 200 adult patients scheduled for surgery will be enrolled and followed for up to five years. During this time, tumor tissue, adjacent non-cancerous tissue, and blood samples will be collected for molecular and biochemical analysis. Serial blood samples taken during follow-up will help explore changes in circulating biomarkers and their relation to disease progression and treatment response. All clinical care and treatment decisions will follow standard practice and will not be influenced by study participation. Participants will have their clinical information, including tumor characteristics, treatments, and disease course, recorded over time. Researchers will analyze molecular features such as circulating tumor DNA, genetic alterations, and gene expression profiles. The main outcome measured is overall survival over five years after surgery, with additional assessments of disease-free and progression-free survival. This study intends to build a valuable resource for identifying biomarkers that may help guide future colorectal cancer care.
Actively Recruiting
This research aims to evaluate how safe and effective upadacitinib is in treating children and adolescents aged 1 to under 18 years with active systemic juvenile idiopathic arthritis sJIA, a severe form of juvenile arthritis that can affect joints and other organs like the liver and heart. The study includes a comparison group receiving tocilizumab, another treatment option, to assess changes in disease activity and adverse events. sJIA is a lifelong condition that can be challenging to manage, making this study important for improving treatment options. Participants are assigned to one of two groups Cohort 1 receives either upadacitinib or tocilizumab, while Cohort 2 receives upadacitinib alone. Upadacitinib is given as oral tablets once daily or oral solution twice daily, and tocilizumab is administered by subcutaneous injection or intravenous infusion following local guidelines. Treatment lasts for 52 weeks, followed by a 30-day safety follow-up period. The study involves about 90 participants across approximately 45 sites worldwide. During the study, participants will attend regular visits or calls at hospitals or clinics where medical assessments will be performed to monitor treatment effects and side effects. Researchers will collect information through questionnaires and clinical evaluations, including measuring the number of active joints, disease activity scores, and inflammation markers. The main outcomes focus on the percentage of participants showing improvement by week 12 and recording any adverse events up to week 52, with ongoing safety monitoring throughout the study.